Lacosamide ( DrugBank: Lacosamide )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	3
46	悪性関節リウマチ	1
149	片側痙攣・片麻痺・てんかん症候群	2
298	遺伝性膵炎	1

2. 筋萎縮性側索硬化症

臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03186040 (ClinicalTrials.gov)	July 13, 2017	5/6/2017	Open-label Clinical Trial of Lacosamide in ALS	Open-label Clinical Trial: Safety of Lacosamide in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: Lacosamide	Chiba University	NULL	Completed	20 Years	N/A	All	7	Phase 1/Phase 2	Japan
2	JPRN-jRCTs031180173	07/07/2017	01/03/2019	Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis	Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis	amyotrophic lateral sclerosis amyotrophic lateral sclerosis;G122	gradual increase of lacosamide from 100mg to 400mg for 4 weeks	Kuwabara Satoshi	NULL	Complete	>= 20age old	Not applicable	Both	30	Phase 1-2	Japan
3	JPRN-UMIN000027476	2017/06/01	01/06/2017	Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis	Open-label clinical trial: safety of lacosamide in patients with amyotrophic lateral sclerosis - Open-label clinical trial of lacosamide in ALS	amyotrophic lateral sclerosis	gradual increase of lacosamide from 100mg to 400mg for 4 weeks	Department of Neurology Chiba University Hospital	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	30	Not selected	Japan

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02342977 (ClinicalTrials.gov)	November 2014	18/12/2014	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:	Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.	Osteoarthritis;Rheumatoid Arthritis;Avascular Necrosis	Drug: Placebo;Drug: Lacosamide	Indiana University School of Medicine	VA Office of Research and Development	Withdrawn	18 Years	70 Years	Both	0	Phase 2	United States

149. 片側痙攣・片麻痺・てんかん症候群

臨床試験数 : 25 / 薬物数 : 35 - (DrugBank : 13) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 22

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-153104	18/3/2016	22/12/2015	AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY	AN OPEN-LABEL, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY	Epilepsy and epilepsy syndrome	Intervention name : SPM927 INN of the intervention : Lacosamide Dosage And administration of the intervention : oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : -	UCB Japan Co., Ltd.	NULL	complete	4		BOTH	239	Phase 3	Japan, Asia except Japan, North America, Europe, Oceania
2	JPRN-JapicCTI-153103	08/12/2015	22/12/2015	A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY	A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LACOSAMIDE AS ADJUNCTIVE THERAPY FOR UNCONTROLLED PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN SUBJECTS WITH IDIOPATHIC GENERALIZED EPILEPSY	Epilepsy and epilepsy syndrome	Intervention name : SPM927 INN of the intervention : Lacosamide Dosage And administration of the intervention : oral administration Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : -	UCB Japan Co., Ltd.	NULL	complete	4		BOTH	242	Phase 3	Japan, Asia except Japan, North America, Europe, Oceania

298. 遺伝性膵炎

臨床試験数 : 95 / 薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05603702 (ClinicalTrials.gov)	November 2022	18/10/2022	STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis	STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis	Chronic Pain;Chronic Pain Syndrome;Chronic Pancreatitis;Hyperalgesia;Opioid Use Disorder;Opioid-Related Disorders;Opioid Dependence;Chronic Abdominal Pain;ERCP;Pancreatic Surgery	Drug: Lacosamide	Indiana University	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Not yet recruiting	18 Years	N/A	All	24	Phase 1	United States

先頭へ